Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: A placebo-controlled clinical trial
Authors:
- Robert H. SquiresRSRobert H. Squires
- Anil DhawanADAnil Dhawan
- Estella AlonsoEAEstella Alonso
- Michael R. NarkewiczMNMichael R. Narkewicz
- Benjamin L. ShneiderBSBenjamin L. Shneider
- Norberto Rodriguez‐BaezNRNorberto Rodriguez‐Baez
- Dominic Dell OlioDODominic Dell Olio
- Saul KarpenSKSaul Karpen
- John BucuvalasJBJohn Bucuvalas
- Steven LobrittoSLSteven Lobritto
- Elizabeth RandERElizabeth Rand
- Philip RosenthalPRPhilip Rosenthal
Open Access
- 10 August 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Hepatology
- Vol. 57 (4) , 1542-1549
Abstract
N-acetylcysteine (NAC) was found to improve transplantation-free survival in only those adults with nonacetaminophen (non-APAP) acute liver failure (ALF) and grade 1-2 hepatic encephalopathy (HE). Because non-APAP ALF differs significantly between children and adults, the Pediatric Acute Liver Failure (PALF) Study Group evaluated NAC in non-APAP PALF. Children from birth through age 17 years with non-APAP ALF enrolled in the PALF registry were eligible to enter an adaptively allocated, doubly masked, placebo-controlled trial using a continuous intravenous infusion of NAC (150 mg/kg/day in 5% dextrose in water [D5W]) or placebo (D5W) for up to 7 days. The primary outcome was 1-year survival. Secondary outcomes included liver transplantation-free survival, liver transplantation (LTx), length of intensive care unit (ICU) and hospital stays, organ system failure, and maximum HE score. A total of 184 participants were enrolled in the trial with 92 in each arm. The 1-year survival did not differ significantly ( P = 0.19) between the NAC (73%) and placebo (82%) treatment groups. The 1-year LTx-free survival was significantly lower ( P = 0.03) in those who received NAC (35%) than those who received placebo (53%), particularly, but not significantly so, among those less than 2 years old with HE grade 0-1 (NAC 25%; placebo 60%; P = 0.0493). There were no significant differences between treatment arms for hospital or ICU length of stay, organ systems failing, or highest recorded grade of HE. Conclusion : NAC did not improve 1-year survival in non-APAP PALF. One-year LTx-free survival was significantly lower with NAC, particularly among thoseKeywords
Funding Information
- NIH (UO1-DK58369, M01-RR00069, M01-RR00037, M01 RR08084)
- General Clinical Research Center Program of the National Center for Research Resources of the NIH
This publication has 36 references indexed in Scilit:
- Glutathione‐dependent reductive stress triggers mitochondrial oxidation and cytotoxicityThe FASEB Journal, 2011
- Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failureHepatology, 2010
- Translational Systems Biology of Inflammation: Potential Applications to Personalized MedicinePersonalized Medicine, 2010
- Translational systems biology of inflammation and healingWound Repair and Regeneration, 2010
- Intravenous N-Acetylcysteine Improves Transplant-Free Survival in Early Stage Non-Acetaminophen Acute Liver FailureGastroenterology, 2009
- Prolonged treatment with N-acetylcystine delays liver recovery from acetaminophen hepatotoxicityCritical Care, 2009
- Etiologies of Acute Liver FailureSeminars in Liver Disease, 2008
- Acute liver failure in children: The first 348 patients in the pediatric acute liver failure study groupThe Journal of Pediatrics, 2006
- AASLD position paperHepatology, 2005
- Acute liver failure in infancy: A 14-year experience of a pediatric liver transplantation centerThe Journal of Pediatrics, 2001